The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension (VISION)
This study has been terminated.
(Terminated due to slow enrollment)
Sponsor:
Actelion
Information provided by:
Actelion
ClinicalTrials.gov Identifier:
NCT00302211
First received: March 10, 2006
Last updated: May 12, 2011
Last verified: May 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this multi-center international trial is to evaluate the safety and effectiveness of adding iloprost or placebo (an inactive substance that contains no active study drug) to sildenafil therapy for pulmonary arterial hypertension (PAH). The study will also examine whether patients on sildenafil can reduce the number of iloprost inhalations from the approved 6 doses per day to 4 doses per day.
| Condition | Intervention | Phase |
|---|---|---|
|
Pulmonary Hypertension |
Drug: Iloprost Inhalation Solution (Ventavis) Drug: Inhaled Placebo Drug: Sildenafil Drug: Bosentan |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Factorial Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of Inhaled Iloprost in Patients With Pulmonary Arterial Hypertension Receiving Oral Sildenafil |
Resource links provided by NLM:
Further study details as provided by Actelion:
Primary Outcome Measures:
- Number of Participants With Change From Baseline to Week 16 in 6-Minute Walk Test (MWT) in Double-blind, Modified Intent To Treat (MITT) Population [ Time Frame: Day 1 to Week 16 ] [ Designated as safety issue: No ]Comparing number of Modified Intent to Treat population in double-blind who improved in the 6-minute walk distance - from baseline distance between 100-450 meters. Any increase in walk distance was considered improvement from baseline. The 6-minute walks were measured in meters using a test administrator, a stop watch, and markers to identify the course.
Secondary Outcome Measures:
- Assess the Efficacy of the Addition of Inhaled Iloprost in Patients With PAH Receiving a Stable Dose of Oral Sildenafil [ Time Frame: Baseline Week 16 up to 48 weeks ] [ Designated as safety issue: No ]The change in 6-minute walk distance (6-MWD) measured after inhalation, following 16 weeks of combination therapy with inhaled iloprost (administered 6 times or 4 times per day) inhaled iloprost plus sildenafil during the open-label extension phase.
| Enrollment: | 67 |
| Study Start Date: | February 2006 |
| Study Completion Date: | November 2009 |
| Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Group A
Inhaled iloprost(5 μg) 6×/day + sildenafil ± bosentan
|
Drug: Iloprost Inhalation Solution (Ventavis)
iloprost inhalation solution (Ventavis) (5 mcg) 6×/day
Drug: Sildenafil
oral sildenafil (dosage between 60 and 300 mg/day)
Drug: Bosentan
oral bosentan (dosage between 62.5 and 125 mg BID)
|
|
Experimental: Group B
Inhaled iloprost (5 μg) 4×/day + sildenafil ± bosentan
|
Drug: Iloprost Inhalation Solution (Ventavis)
iloprost inhalation solution (Ventavis) (5 mcg) 4×/day
Drug: Sildenafil
oral sildenafil (dosage between 60 and 300 mg/day)
Drug: Bosentan
oral bosentan (dosage between 62.5 and 125 mg BID)
|
|
Placebo Comparator: Group C
Inhaled placebo 6×/day + sildenafil ± bosentan
|
Drug: Inhaled Placebo
inhaled placebo 6×/day (5 mcg)
Drug: Sildenafil
oral sildenafil (dosage between 60 and 300 mg/day)
Drug: Bosentan
oral bosentan (dosage between 62.5 and 125 mg BID)
|
Eligibility| Ages Eligible for Study: | 12 Years to 85 Years (Child, Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Aged 12-85 years; of either gender.
- Confirmed PAH due to idiopathic pulmonary arterial hypertension (IPAH) or familial pulmonary arterial hypertension (FPAH).
- 6-minute walk distance (6-MWD) between 100-450 meters at screening.
- On a stable dose of sildenafil, with or without Bosentan.
Exclusion Criteria:
- Any treatment for PAH with prostacyclins, prostacyclin analogues, endothelin-1 antagonists, or phosphodiesterase-5 (PDE-5) inhibitors other than sildenafil within the past 12 weeks.
- Pulmonary hypertension due to conditions other than those stated in inclusion criteria.
- Additional PAH medications added within the past 12 weeks
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00302211
Show 34 Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00302211
Show 34 Study Locations
Sponsors and Collaborators
Actelion
Investigators
| Study Chair: | Robyn J Barst, MD | Steering Committee Advisor |
| Study Chair: | David B Badesch, MD, FACP, FCCP | Steering Committee Advisor |
| Principal Investigator: | Ardeschir Ghofrani, MD | Medizinische Klinik und Poliklinik II Univer GieBen |
| Principal Investigator: | Nazzareno Galie, MD | Istituto Malattie Apparato Cardio Univ di Bologna |
More Information
Additional Information:
| Responsible Party: | Actelion Pharmaceuticals US/Sponsor, Actelion Pharmaceuticals US |
| ClinicalTrials.gov Identifier: | NCT00302211 History of Changes |
| Other Study ID Numbers: | C200-006 |
| Study First Received: | March 10, 2006 |
| Results First Received: | May 27, 2010 |
| Last Updated: | May 12, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Actelion:
|
PAH Pulmonary Arterial Hypertension |
Additional relevant MeSH terms:
|
Hypertension Hypertension, Pulmonary Familial Primary Pulmonary Hypertension Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Pharmaceutical Solutions Sildenafil Citrate Iloprost |
Bosentan Vasodilator Agents Phosphodiesterase 5 Inhibitors Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Urological Agents Platelet Aggregation Inhibitors Antihypertensive Agents Endothelin Receptor Antagonists |
ClinicalTrials.gov processed this record on September 29, 2016